At this time, companies are not allowed to make generic versions of Tyzeka (telbivudine), as this drug is protected by patents. The earliest estimated date when a generic version might become available is after the first patent expires in August 2019. However, lawsuits, new patents, or other circumstances may change this date.
Can I Buy Generic Tyzeka?Tyzeka® (telbivudine) is a prescription medication approved for treating chronic hepatitis B infection in certain people 16 years of age and older. It belongs to a group of medications known as nucleoside reverse transcriptase inhibitors (NRTIs), also called nucleoside analogues.
Tyzeka is made by Novartis Pharmaceutical Corporation. It is protected by patents that prevent any generic Tyzeka from being manufactured in the United States.
When Will a Generic Version Be Available?Tyzeka is protected by a few different patents. The first patent expires in August 2019, which is the earliest predictable date that a generic version could become available. However, this could change, depending on many factors, such as lawsuits or additional patents for new Tyzeka uses. Once the drug goes off-patent, there may be several companies that will manufacture a generic Tyzeka product.
Is Telbivudine a Generic Form of Tyzeka?No -- telbivudine is the active ingredient in Tyzeka, not a generic version of it. What can be confusing is that the active ingredient of a drug is often referred to as the "generic name."
The generic name is different from a generic version of a medicine. In order for there to be a generic version, the original medicine must have gone off-patent, and another company besides the original manufacturer must make the product.